Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

Saved in:
Bibliographic Details
Title: Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.
Authors: Kim H; Division of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea., Oum C; Lunit Inc., Seoul, South Korea., Cho SI; Lunit Inc., Seoul, South Korea., Jung W; Lunit Inc., Seoul, South Korea., Chon HJ; Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea., Lee MA; Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea., Im HS; Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, South Korea., Kim MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Nam T; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea., Ock CY; Lunit Inc., Seoul, South Korea., Choi HJ; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Lee CK; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
Source: JCO precision oncology [JCO Precis Oncol] 2025 Oct; Vol. 9, pp. e2500510. Date of Electronic Publication: 2025 Oct 02.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-4284
DOI:10.1200/PO-25-00510